eGene will be Granted Chinese Patent for DNA Analyzer Technology
News Mar 28, 2006
eGene Inc. has announced the Company has received confirmation from the China Patent Office of its decision to grant a patent for "Optical detection in a multi-channel bio-separation system." This marks the Company's eighth patent worldwide.
Ming S. Liu, acting CEO of eGene, made the announcement noting, "We continue to strengthen our patent portfolio with the addition of this Chinese patent."
"We believe our portable HDA-GT12™ Genetic Analyzer has potential for any number of important uses, among them controlling transmission of infectious diseases through use at locations where DNA can be screened for viral or bacterial signatures; assisting in the development of 'designer drugs' where a patient's DNA is compared to that of a specific drug to determine if that drug will be effective on that individual or if side effects might occur; academic research; and criminal DNA analysis."
The HDA-GT12™ Genetic Analyzer analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP.
It performs RNA and oligonucleotide quality checks, as well as DNA sample screening, high-resolution DNA fragment analysis (2-5bp) and large DNA fragments analysis (up to 10Kb).
The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and is designed to ensure quality of fragmented cRNA.
The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
New Inherited Neurodevelopmental Disease DiscoveredNews
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE